
Ecovyst accelerates top-line growth with 51% Q3 revenue surge to $308.6M
Key points
- Ecovyst (NYSE:ECVT) reported third-quarter 2026 sales of $308.6 million, up 51% year over year, while net income from continuing operations increased to $18.4 million.
- Adjusted EBITDA rose 6% to $61.2 million, although adjusted free cash flow declined to $32.4 million for the first nine months.
- Ecovyst raised its 2026 sales forecast to $1.05 billion–$1.07 billion and adjusted EBITDA guidance to $208 million–$212 million.
Ecovyst (NYSE:ECVT) reported third-quarter 2026 sales of $308.6 million, up 51% year over year, while net income from continuing operations increased to $18.4 million from $0.2 million.
Adjusted EBITDA increased 6% to $61.2 million from $57.5 million, while adjusted earnings per share reached $0.23, compared with analyst expectations of $0.21.
The sales increase included approximately $67 million in higher sulfur-cost pass-through and contributions from Calabrian, which Ecovyst acquired on June 30, 2026, making the third quarter its first full reporting period with the business.
Nine-month operating cash flow from continuing operations increased to $80.7 million from $77 million, while adjusted free cash flow declined to $32.4 million from $42.4 million and net debt leverage increased to 2.1 times from 1.2 times at year-end 2025.
Ecovyst raised its 2026 sales forecast to $1.05 billion–$1.07 billion and adjusted EBITDA guidance to $208 million–$212 million, partly reflecting a turnaround postponed until early 2027.
Ecovyst supplies sulfuric acid, sulfur dioxide and specialty catalyst products and services to customers in refining, petrochemicals, industrial processing and mining markets.
Its operations include virgin sulfuric acid production, sulfuric acid regeneration, catalyst services and the Calabrian sulfur dioxide business, with its strategy focused on expanding specialty chemical operations and improving operating cash generation.
Frequently asked questions
More from United States
ACM Research boosts 2026 revenue guidance to $1.28 billion
Canadian Natural reports $3 billion Q3 profit, reaches debt target
Stoneridge raises 2026 revenue guidance to $700 million
Comstock Resources Q3 profit hits $22.3 million
TWFG raises 2026 organic growth guidance to 17%
ANI Pharmaceuticals offers $560 million for Egetis



